The influence of radiotherapy duration on the outcomes of limited-disease small-cell lung cancer has been controversial. In this study, all 81 patients completed 45 Gy in 30 fractions and concurrent chemotherapy of platinum and etoposide. The median radiotherapy duration was 25 days. The median survival time was 30 months, and the radiotherapy duration was identified as one of the significant survival predictors (hazard ratio, 1.08; 95% confidence interval, 1.01-1.15). The main reason for prolonging the radiotherapy duration was febrile neutropenia, not esophagitis. Background: The hypothesis of this retrospective study was that the duration of twice-daily (BID) thoracic radiotherapy (TRT) and time from the start of any treatment to the end of chest irradiation (SER) would predict outcomes in limited-disease small-cell lung cancer. Materials and Methods: All 81 patients received 45 Gy in 30 fractions BID with a 6-hour interval and concurrent chemotherapy of platinum and etoposide. Results: The median radiotherapy duration was 25 days (range, 21-38 days). The 5-year overall survival rates were 26.2% (95% confidence interval [CI], 14.3%-38.0%), and the median survival time was 30 months (95% CI, 15.5-44.5 months). Using multivariate regression analysis, the significant predictors of survival were the sum of the diameters of the primary tumor and metastatic lymph nodes, male gender, age 60 years, and the duration of BID-TRT (hazard ratio [HR], 1.15; 95% CI, 1.06-1.25; HR, 2.38; 95% CI, 1.13-5.02; HR, 2.38; 95% CI, 1.10-5.17; and HR, 1.08; 95% CI, 1.01-1.15, respectively). A total of 70 of 81 patients (86%) received radiotherapy during the first chemotherapy cycle. The median SER was 29 days (range, 21-109 days). The 5-year local control rate was 48.7% (95% CI, 33.9%-63.6%). The significant predictors of local control were the sum of the diameters of the primary tumor and metastatic lymph nodes, age 60 years, and SER (HR, 1.18; 95% CI, 1.06-1.31; HR, 4.18; 95% CI, 1.23-14.24; and HR, 1.02; 95% CI, 1-1.04, respectively). Conclusions: The duration of BID-TRT and SER were identified as one of the significant predictors of survival and local control in limited-disease small-cell lung cancer treated with concurrent chemoradiotherapy at 45 Gy in 30 fractions, respectively.
Introduction
The standard treatment for limited-disease small-cell lung cancer (LD-SCLC) is chemoradiotherapy, 1 and the standard radiotherapy regimen used is twice-daily (BID) thoracic radiotherapy (TRT). It is generally delivered at a total dose of 45 Gy in 30 fractions over 3 weeks to decrease the duration of radiotherapy relative to conventionally fractionated radiotherapy. 2 However, a pattern of care study revealed that BID-TRT was performed on 21.5% of patients with small-cell lung cancer, 3 and the suggested reasons for this were as follows: it was challenging to perform BID radiotherapy in clinical practice; there was frequent chemoradiotherapy-induced severe esophagitis in the BID-TRT group; or there was an alternative choice involving once-daily high-dose radiotherapy. 4 Thus, few studies have investigated the predictors of outcomes in LD-SCLC patients treated with BID-TRT. 5 The duration of BID-TRT in LD-SCLC has not yet been established as a predictor of outcomes. Therefore, we retrospectively investigated the predictors of outcomes in LD-SCLC including the duration of BID-TRT thoracic radiotherapy. In addition, we included time from the start of any treatment to the end of chest irradiation (SER) 6 in these analyses.
Materials and Methods
A total of 105 patients with LD-SCLC received radiotherapy between January 2004 and October 2013 at our institution. Of these, 81 (77%) were treated with concurrent chemoradiotherapy at 45 Gy in 30 fractions and were included in this retrospective study (Table 1) . Institutional Review Board approval was obtained for this study. In this study, LD-SCLC was defined as disease confined to the ipsi-hemithorax with or without ipsilateral hilar nodes, mediastinal nodes, or bilateral supraclavicular nodes metastasis excluding the bilateral hilar nodes or malignant pleural effusion. The diagnosis of SCLC was confirmed by histologic or cytologic findings. Eligibility criteria were as follows: (1) no previous treatment including surgery or stereotactic ablative body radiotherapy for LD-SCLC; and (2) an Eastern Cooperative Group Performance Status (PS) of 0 to 2. All patients underwent the following pre-therapeutic procedures: a physical examination; chest radiography; fiberoptic bronchoscopy; complete blood cell count and biochemical tests including tumor markers; electrocardiography; computed tomography (CT) imaging of the chest and abdomen; CT or magnetic resonance imaging of the brain; and bone scintigraphy or positron emission tomography. All patients were hospitalized for chemoradiotherapy and quit smoking during the treatment. A hematologic status, which included a white blood cell count of > 3500/mm 3 , platelet count of > 100,000/mm 3 , and hemoglobin level of > 10 g/ dL, was required. No patients received prophylactic granulocytecolony stimulating factor (G-CSF) before chemoradiotherapy. When patients developed grade 4 neutropenia, sterilized food was prepared, and prophylactic antibiotics were used. When patients developed febrile neutropenia, which was defined as an axillary temperature of 37.5 C with grade 4 neutropenia during chemoradiotherapy, G-CSF and empiric broad-spectrum antibiotics were primarily administered. When febrile neutropenia or grade 3 non-hematologic adverse events excluding nausea, vomiting, appetite loss, and elevated creatinine or liver enzymes developed, BID-TRT Duration as Survival Predictor in LD-SCLC radiotherapy was generally interrupted. Recovery from febrile neutropenia was defined as an axillary temperature of < 37 C with a neutrophil count of > 500/mm 3 . LD-SCLC combined with interstitial pneumonia was principally contraindicated for chemoradiotherapy because of an increase in the risk of the acute exacerbation of interstitial pneumonia 7 ; however, when the patient and family understood this risk and still wished to receive standard treatment, we treated theses as special cases and administrated chemoradiotherapy. Follow-up was performed every month for the first year, every 2 or 3 months for the second year, every 3 or 4 months for the third to fifth year, and every 6 months after the fifth year. Close follow-up was performed for early detection of the recurrence. No patients were lost to follow-up. Adverse events were evaluated using Common Terminology Criteria for Adverse Events, Version 4.0. The follow-up time was counted from the day any anticancer treatment was started. Any death was counted as an event in the overall survival rate. Any death or progression, including distant metastasis, was counted as an event in the progression-free survival rate. Any progression in the radiotherapy field was counted as an event in the local control rate.
Radiotherapy
Thoracic radiotherapy was performed BID at a dose of 1.5 Gy per fraction with an interval of 6 hours between fractions to a total dose of 45 Gy in 30 fractions given over 3 weeks. The duration of BID-TRT was defined as days between the start of TRT and the end of TRT. Radiotherapy was administrated on 5 consecutive days per week, excluding Saturdays, Sundays, and holidays. For example, the holidays in 2004 were as follows; January 1, 2, 3, 12; February 11; March 20; April 29; May 3, 4, 5; July 19; September 20, 23; October 11; November 3, 23; and December 23, 29, 30, and 31. Radiotherapy was performed using a linear accelerator with an energy of 10 MV photons. After 30 Gy in 20 fractions had been delivered, the radiotherapy field was changed to avoid irradiating the spinal cord from anterior-posterior opposed large fields (which included the elective nodes) to parallel opposed oblique small fields (which included only the primary tumor and metastatic lymph nodes). However, 1 patient whose tumor had aggressively invaded the contralateral mediastinum was treated using large fields until 36 Gy in 24 fractions had been delivered and then using small fields until 45 Gy in 30 fractions had been delivered. Another patient with stage I disease received radiotherapy for the primary tumor only without elective node irradiation until 45 Gy in 30 fractions had been delivered. A 3-dimensional CT simulation or 2-dimensional radiograph simulation were used for treatment planning. The 2-dimensional radiograph simulation was used for the first 2 years of this study, but all patients subsequently received 3-dimensional CT simulation. In the 3-dimensional CT simulation, the clinical target volume (CTV) 1 was typically a 0.5-cm expansion of the gross tumor volume including the primary tumor and metastatic lymph nodes; the planning target volume (PTV) 1 was then a 0.5 to 1 cm expansion of the CTV1. The CTV2 was subsequently defined as elective hilar, mediastinal, or supraclavicular lymph nodes plus the CTV1. The CTV2 included the ipsilateral hilar lymph nodes, subcarinal nodes, and lower paratracheal nodes. The CTV2 also included the aortopulmonary window and para-aortic nodes in all left primary tumors and some right primary tumors. The CTV2 included or excluded the upper paratracheal lymph nodes and supraclavicular lymph nodes, depending on the decision of the oncologists regarding tumor spreading. The PTV2 was typically defined as a 0.5 to 1 cm expansion of the CTV2. Elective nodal irradiation was performed at doses of 30 Gy for the PTV2, and then boost irradiation was performed at total doses of 45 Gy for the PTV1. In the 2-dimensional radiograph simulation, the radiotherapy field included the tumor volume with a 1.5 cm margin around the mass, and the elective nodal irradiation included the ipsilateral hilar area, subcarinal area, and lower paratracheal area. All left-sided tumors included the aortic arch and aortopulmonary window area. Whether the supraclavicular and upper tracheal areas were included or excluded depended on the decision of the oncologists regarding tumor spreading. Slotman et al 8 showed the benefit of prophylactic cranial irradiation in patients with extensive-disease SCLC after a response to chemotherapy. The definition of a response, indicating good responders or stable disease, differs between institutions. In our institution, prophylactic cranial irradiation was administrated to good responders.
Chemotherapy
The concurrent chemotherapy regimen mainly consisted of cisplatin and etoposide. In patients aged > 75 years, with a low performance status, low renal function (creatinine clearance < 60 mL/min), a syndrome of the inappropriate secretion of antidiuretic hormone, or other severe complications, the second choice for concurrent chemotherapy consisted of carboplatin and etoposide. The first-choice chemotherapy regimen consisted of 80 mg/m 2 of During the second cycle of chemotherapy 6 (7)
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Clinical Lung Cancer March 2017 -e119 intravenous cisplatin on day 1 and 100 mg/m 2 of intravenous etoposide on days 1 to 3. The second-choice chemotherapy regimen consisted of intravenous carboplatin with an area under the curve (AUC) of 5 on day 1 and 80 mg/m 2 etoposide on days 1 to 3. The dose of cisplatin, etoposide, or carboplatin in subsequent cycles was reduced by 10 to 20 mg/m 2 or AUC of 1 from the planned dose when grade 4 hematologic toxicity or grade 3 non-hematologic adverse events occurred. Chemotherapy was interrupted or changed as a result of prolonged hematologic toxicity, severely elevated creatinine, pulmonary infection, or chemoradiotherapyinduced pneumonitis. Chemotherapy was principally performed in 4 cycles every 3 to 4 weeks. The timing of TRT was primarily during the first cycle of concurrent chemotherapy. When the oncologists determined that the tumor occupied more than one-half of the ipsilateral lung or when patients were considered too elderly to perform the first cycle of chemoradiotherapy, a second or later cycle of chemoradiotherapy was administrated. The duration of chemotherapy was defined as days between the first day of the first cycle of chemotherapy and the first day of the last cycle of chemotherapy.
Statistical Analysis
The overall survival, local control, and progression-free survival rates were estimated using the Kaplan-Meier method, and the significant differences were analyzed using the log-rank test. Cox multivariate and univariate regression analyses were used to assess overall survival, local control, and progression-free survival. The forward stepwise method with likelihood ratios was adopted in the regression analyses. Receiver operating characteristics analysis was used to decide the optimal cut-off value of the duration of BID-TRT. A P-value of < .05 was considered significant using a 2-sided test. Statistical analyses were performed using SPSS, version 19.0 (IBM, Armonk, NY) and EZR (Saitama Medical Center, Jichi Medical University), 9 a modified version of R commander designed to add statistical functions frequently used in biostatistics, including a graphical user interface for R (The R Foundation for Statistical Computing). The Spearman correlation coefficient matrixes were produced in order to investigate relationships among the time related factors including the duration of BID-TRT, SER, performing radiotherapy during the second or later cycle of chemotherapy, and including holidays during radiotherapy (Figure 1 ). The combination of the duration of BID-TRT and SER had relatively high correlation coefficients (0.697). The other combination of SER and performing radiotherapy during the second or later cycle of chemotherapy had also relatively high correlation coefficients (0.596). Thus, these combinations were excluded from Cox multivariate regression analyses in order to control confounding factors that may negatively affect the generalizability of the Cox multivariate regression model.
Multivariate Cox regression analyses were performed using significant or marginally significant factors with P-values that were less than .06 in Cox univariate regression analyses. Furthermore, the duration of BID-TRT, which was the focus of this study, was included in Cox multivariate regression analyses on overall survival and progression-free survival even though it was not significant in the Cox univariate regression analyses (Tables 2 and 3 ). However, the duration of BID-TRT was excluded from Cox multivariate regression analyses on local control (Table 4) because SER was a significant factor in the Cox univariate regression analysis of local control and had relatively high Spearman correlation coefficients with the duration of BID-TRT ( Figure 1 ). Also, performing radiotherapy during the second or later cycle of chemotherapy was excluded from Cox multivariate regression analyses on local control (Table 4) in spite of its marginal significance in the Cox univariate regression analysis because it had relatively high Spearman correlation coefficients with SER ( Figure 1 ).
Results
The median follow-up period was 21 months (range, 2-117 months). All 81 patients completed radiotherapy with a total dose of 45 Gy in 30 fractions. The median duration of BID-TRT was 25 days (range, 21-38 days), and its distribution is shown in Figure 2 . Chemoradiotherapy-induced adverse events are listed in Table 5 . The 2-, 3-, and 5-year overall survival rates in all 81 patients were 55.8% (95% confidence interval [CI], 44.0%-67.6%), 44.9% (95% CI, 32.6%-57.2%), and 26.2% (95% CI, 14.3%-38.0%), respectively, and the median survival time was 30 months (95% CI, 15.5-44.5 The reasons for prolonging the duration of BID-TRT were toxicity-interrupting radiotherapy and holidays. Chemoradiotherapy-induced grade 3 esophagitis was observed in 1 patient (1%) ( Table 5 ). Thus, that was not a main factor prolonging the duration of BID-TRT. The most frequent toxicity that prolonged the duration of BID-TRT was febrile neutropenia, which accounted for 70% of cases (35 of 50) of toxicity-interrupting radiotherapy. Radiotherapy was generally interrupted until recovery from febrile neutropenia; however, the timing to re-start radiotherapy depended on the decision of each oncologist. The 
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Clinical Lung Cancer March 2017 -e121 duration of BID-TRT would have decreased by 1 to 3 days in the 14 patients with febrile neutropenia if radiotherapy had been immediately re-started after recovery from febrile neutropenia. The mean ages in patients with and without febrile neutropenia were 67 years and 64 years, respectively (P ¼ .079; not significant). The percentages of the patients with a PS 0 among the patients with and without febrile neutropenia were 51% (20 of 39 patients) and 40% (17 of 42 patients), respectively (P ¼ .329; not significant).
The median survival time in the 30 patients whose duration of BID-TRT did not include holidays, and that in the 51 patients whose duration of BID-TRT included holidays was 37 months (95% CI, 23.9-50.1 months) and 29 months (95% CI, 19.0-39.0 months), respectively (P ¼ .535; not significant) (see Supplemental Figure 1 in the online version). The median survival time in the 31 patients whose duration of BID-TRT was not prolonged owing to toxicity and that in the 50 patients whose duration of BID-TRT was prolonged owing to toxicity was 30 months (95% CI, 14.0-46.0 months) and 29 months (95% CI, 13.1-44.9 months), respectively (P ¼ .348; not significant) (see Supplemental Figure 2 in the online version).
The 2-, 3-, and 5-year local control rates in all 81 patients were 58.1% (95% CI, 44.7%-71.5%), 52.2% (95% CI, 37.9%-66.5%), and 48.7% (95% CI, 33.9%-63.6%), respectively, and the median local control time was 41 months (95% CI was not calculated) ( Figure 3) . The Cox multivariate regression analysis identified as significant predictors of local control the sum of the diameters of the primary tumor and metastatic lymph nodes, age 60 years, and SER (Table 4) .
The 2-, 3-, and 5-year progression-free survival rates in all 81 patients were 28.0% (95% CI, 17.5%-38.5%), 24.5% (95% CI, 
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14.2%-34.7%), and 19.0% (95% CI, 8.7%-29.4%), respectively, and the median progression-free survival time was 11 months (95% CI, 8.3%-13.7%) (Figure 3 ). The Cox multivariate regression analysis identified as significant predictors of progression-free survival performing prophylactic cranial irradiation and the irradiated volume of the body (Table 3) .
Discussion

Significance of the Duration of BID-TRT and SER
Multivariate analyses identified the following significant predictors of survival in LD-SCLC patients; the sum of the diameters of the primary tumor and metastatic lymph nodes (a tumor factor); male gender and age 60 years (patient factors); and the duration of BID-TRT (a treatment factor). The influence of the duration of radiotherapy on the outcomes of LD-SCLC, which is generally considered to be a rapidly proliferating cancer, has been controversial. Actually, Bogart et al 10 reported that interruptions in oncedaily thoracic radiotherapy did not correlate with the outcomes of LD-SCLC patients at a total dose of 50 Gy delivered in 25 fractions over 5 weeks (once-daily conventional schedules involving 2 Gy/ fraction). They showed that the median survival times were 21.7, 18.1, and 23.8 months in the 0 to 3 days interrupted group, the 4 to 10 days interrupted group, and the > 10 days interrupted group, respectively. These differences were not significant. However, the opposite findings were obtained using an accelerated radiotherapy regimen. Videtic et al 11 demonstrated that treatment interruptions to palliate the toxicity of concurrent chemoradiotherapy for LD-SCLC decreased survival and disease control at mainly 40 Gy delivered in 15 fractions over 3 weeks (once daily accelerated schedules involving 2.67 Gy/fraction). They reported that the 13 was shorter than that in oropharyngeal cancer of 96 days. 14 We speculated that cancers such as small-cell lung cancer, which is more rapidly proliferating than head and neck cancer, had a shorter duration of accelerated tumor clonogen repopulation. Thus, the duration of radiotherapy may biologically impact on SCLC cell survival. Although a meta-analysis by De Ruysscher et al 6 showed that SER was the most important predictor of survival in LD-SCLC patients, this meta-analysis did not reveal whether the actual duration of BID-TRT was a significant predictor of survival. Our study is unique because all patients received BID-TRT of 45 Gy in 30 fractions, and the actual duration of radiotherapy are analyzed. In addition, although De Ruysscher et al 6 reported that SER did not correlate with local control, our study showed that SER did correlate with local control.
Febrile Neutropenia Prolonged the Duration of BID-TRT
In the present study, febrile neutropenia was the main reason for the prolongation of the duration of BID-TRT. In addition, the duration of BID-TRT would have decreased in some patients with febrile neutropenia if radiotherapy had been re-started immediately after recovery from febrile neutropenia. Careful monitoring of the white blood cell count and body temperature is necessary to safely re-start radiotherapy under these circumstances. Washing the hands and throat, eating sterilized food, using an isolator, using a clean room, and taking prophylactic and empiric antibiotics may be essential for decreasing the frequency and recovery recommended that prophylactic G-CSF should not be indicated for LD-SCLC, therapeutic G-CSF was essential for recovery from febrile neutropenia with careful monitoring for thrombocytopenia. As collateral evidence, Clark et al 16 reported that G-CSF shortened the hospitalization time and neutrophil recovery time in patients with febrile neutropenia. In the present study, therapeutic G-CSF was not a significant factor affecting survival. In the future, the palliation of myelosuppression may be possible by reducing the radiation dose to the vertebral column using intensity-modulated radiation therapy. In the present study, the severe esophagitis was so rare that no correlation was observed with prolongation of the duration of BID-TRT. The frequency of severe esophagitis in our study or others from Eastern Asia 17,18 was 1% to 4% lower than that reported in Western countries (19%-33%). 2, 5 The reason for this currently remains unclear; however, we speculated that the difference may be related to the lower rate of gastroesophageal reflux disease in Asian countries than in Western countries. 19 
Conclusions
The interpretation of the effects of the duration of radiotherapy on the outcomes of LD-SCLC was valid because the total dose, number of fractions of radiation, and concurrent chemotherapy of platinum and etoposide were not varied. The duration of BID-TRT at a total dose of 45 Gy in 30 fractions and SER were one of the significant predictors of survival and local control in patients with LD-SCLC, respectively. Febrile neutropenia was the main factor responsible for prolonging the duration of BID-TRT. Re-starting radiotherapy immediately after recovery from febrile neutropenia needs to be considered in order to improve the prognosis of patients with LD-SCLC.
Clinical Practice Points
The topic of radiotherapy duration on the outcomes in limiteddisease small-cell lung cancer (LD-SCLC) remains unresolved and requires further research. One study revealed that interruptions in once-daily thoracic radiotherapy did not correlate with the outcomes of LD-SCLC patients at a total dose of 50 Gy in 25 fractions over 5 weeks. The present study contains the opposite new findings about the significance of the duration of twice-daily thoracic radiotherapy in relation to the survival of patients with LD-SCLC receiving standard concurrent chemoradiotherapy (platinum and etoposide at 45 Gy in 30 fractions over 3 weeks). Our interpretation about radiotherapy duration were valid because all patients completed 45 Gy/30 fractions. Additionally, we detected that febrile neutropenia, not esophagitis, was a main factor responsible for the prolongation of the radiotherapy duration. For minimizing the negative influence of febrile neutropenia on the radiotherapy duration, radiotherapy should be re-started immediately after recovery from febrile neutropenia. Any support care should be done to decrease the frequency and recovery time of febrile neutropenia. Although one study previously recommended that prophylactic granulocyte-colony stimulating factor (G-CSF) should not be indicated for LD-SCLC, therapeutic G-CSF was essential for recovery from febrile neutropenia with careful monitoring for thrombocytopenia. In the present study, therapeutic G-CSF was not a significant factor affecting survival. The palliation of myelosuppression may be possible by reducing the radiation dose to the vertebral column using intensity modulated radiation therapy. Our new findings will contribute to improve the prognosis in LD-SCLC.
